Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward



  • Comorbidity and Injured Individuals: Part one

    by
    • Medicare Insights
    • The Policy Matters team
    | Oct 09, 2019
    Tag Icon
    MSA, Medicare Set-Aside, Medicare Insights, Comorbidities, clinical info, Clinical
    Comorbid conditions in workers’ compensation and auto no-fault can create a trifecta of negative outcomes and aggravate an already difficult situation for an injured individual. In Part one of our series on comorbidities, we will define what they are and describe the three ways comorbidities can make a bad situation worse.


  • Novartis halts distribution of ranitidine products, generic for Zantac®, as precaution during investigation of possible contamination

    by
    • Optum for Workers' Compensation
    | Sep 19, 2019
    Tag Icon
    Pharmacy, Clinical, recall, FDA
    On September 18, 2019, Novartis announced it is stopping the distribution of its Sandoz division’s ranitidine, generic for Zantac®, until further notice. This decision was made as a result of the U.S. Food and Drug Administration (FDA) statement on September 13 that low levels of a human carcinogen were found in some ranitidine products.


  • New federal workers’ comp opioid policy imposes additional limitations

    by
    • The Policy Matters team
    | Sep 17, 2019
    Tag Icon
    Government Affairs, Opioids, Department of Labor
    A new opioid policy imposing additional fill limitations and reducing the 60-day period for required prior approval has been announced by the U.S. Department of Labor, Office of Workers’ Compensation Programs (OWCP), Division of Federal Employees’ Compensation (DFEC).


  • DEA moving to increase marijuana research

    by
    • The Policy Matters team
    | Sep 11, 2019
    Tag Icon
    Medical Marijuana, DEA, Government Affairs
    The Drug Enforcement Administration (DEA) recently announced it is moving forward with efforts to increase scientific and medical research of marijuana.


  • New York Workers’ Compensation Board provides overview of Drug Formulary Prior Authorization System

    by
    • The Policy Matters team
    | Sep 04, 2019
    Tag Icon
    State Formulary, Government Affairs, New York, Drug Formulary
    As the procedures to implement the New York Workers’ Comp Drug Formulary continue to evolve, the New York Workers’ Compensation Board (WCB) has issued updated guidance and clarified requirements for all stakeholders. The WCB just released registration requirements and the roles various individuals and entities will play not only now, but once the formulary goes into effect in December 2019.


  • Pfizer issues medication recall for two lots of Relpax® 40 mg tablets

    by
    • OWCA
    | Aug 30, 2019
    Tag Icon
    Clinical
    On August 15, 2019, the U.S. Food and Drug Administration (FDA) announced that Pfizer Inc. issued a voluntary recall for two lots of Relpax® (eletriptan) 40 mg tablets to the patient level.


  • New York Workers’ Compensation Board provides additional clarification on mandated drug formulary notifications

    by
    • Optum for Workers' Compensation
    | Aug 15, 2019
    Tag Icon
    Pharmacy, New York, Government Affairs, formulary, Clinical
    The New York State Workers’ Compensation Board (WCB) has released information on how to implement the mandated communications to claimants and their prescribers who will be impacted when the new drug formulary goes into effect in December 2019.



Stay informed by receiving latest updates

Do you have a question about a blog post?

See more insights